Canine amniotic membrane-derived mesenchymal stem cells ameliorate atopic dermatitis through regeneration and immunomodulation

Canine amniotic membrane-derived mesenchymal stem cells ameliorate atopic dermatitis through regeneration and immunomodulation

Mesenchymal stem cells (MSCs) are a promising tool for treating immune disorders. However, the immunomodulatory effects of canine MSCs compared with other commercialized biologics for treating immune disorders have not been well studied. In this study we investigated the characteristics and immunomo...

Full description

Saved in:
Bibliographic Details
Published in:Veterinary research communications Vol. 47; no. 4; pp. 2055 - 2070
Main Authors: Kim, Min Soo, Kong, Dasom, Han, Myounghee, Roh, Kyounghwan, Koo, Hojun, Lee, Seunghee, Kang, Kyung-Sun
Format: Journal Article
Language:English
Published: Dordrecht Springer Netherlands 01-12-2023
Springer Nature B.V
Subjects:
Amnion
Amniotic membrane
Atopic dermatitis
Biomedical and Life Sciences
Cell proliferation
Dermatitis
Eczema
Gene expression
Immunomodulation
Inflammation
Janus kinase
Kinases
Life Sciences
Lymphocytes T
Mesenchymal stem cells
Oral administration
Peripheral blood mononuclear cells
Side effects
Stem cells
Transforming growth factor-b1
Veterinary Medicine/Veterinary Science
Zoology
Atopic dermatitis (AD)
Mesenchymal stem cells (MSCs)
Oclacitinib (OCL)
Canine amnion membrane (cAM)
Canine
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mesenchymal stem cells (MSCs) are a promising tool for treating immune disorders. However, the immunomodulatory effects of canine MSCs compared with other commercialized biologics for treating immune disorders have not been well studied. In this study we investigated the characteristics and immunomodulatory effects of canine amnion membrane (cAM)-MSCs. We examined gene expression of immune modulation and T lymphocytes from activated canine peripheral blood mononuclear cell (PBMC) proliferation. As a result, we confirmed that cAM-MSCs upregulated immune modulation genes ( TGF-β1 , IDO1 and PTGES2 ) and suppressed the proliferation capacity of T cells. Moreover, we confirmed the therapeutic effect of cAM-MSCs compared with oclacitinib (OCL), the most commonly used Janus kinase (JAK) inhibitor, as a treatment for canine atopic dermatitis (AD) using a mouse AD model. As a result, we confirmed that cAM-MSCs with PBS treatment groups (passage 4, 6 and 8) compared with PBS only (PBS) though scores of dermatologic signs, tissue pathologic changes and inflammatory cytokines were significantly reduced. In particular, cAM-MSCs were more effective than OCL in the recovery of wound dysfunction, regulation of mast cell activity and expression level of immune modulation protein. Interestingly, subcutaneous injection of cAM-MSCs induced weight recovery, but oral administration of oclacitinib induced weight loss as a side effect. In conclusion, this study suggests that cAM-MSCs can be developed as a safe canine treatment for atopic dermatitis without side effects through effective regeneration and immunomodulation.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0165-7380
1573-7446
DOI:10.1007/s11259-023-10155-5